Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically or cytologically confirmed breast adenocarcinoma who are candidates for paclitaxel single agent chemotherapy for metastatic breast cancer~* ECOG performance \< 2~* One or more metastatic tumors measurable by RECIST criteria on CT scan or MRI (Phase 2 part only)~* Life expectancy of at least 6 months~* Age \> 18 years~* Signed, written IRB-approved informed consent~* A negative serum pregnancy test (if applicable)~* Acceptable liver function:~* Bilirubin within normal limit~* AST (SGOT), ALT (SGPT) and Alkaline phosphatase \< 2.0 times the institution's upper limit of normal~* Acceptable renal function:~* Serum creatinine within normal limits, OR calculated creatinine clearance \> 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal~* Acceptable hematologic status:~* Granulocyte \> 1500 cells/uL~* Platelet count \> 100,000 plt/uL~* Hemoglobin \> 9.0 g/dL~* Acceptable coagulation status:~* PT within normal limits~* PTT within normal limits~* For women of child-bearing potential, the use of effective contraceptive methods during the study~* Prior radiotherapy is allowed provided disease progression outside the radiation field has been documented, and treatment completed at least 2 weeks prior to registration~Exclusion Criteria:~* Prior taxane chemotherapy for metastatic disease.~* More than one prior chemotherapy regimen for metastatic disease~* Active progressive brain metastases including the presence of any related symptoms or need for corticosteroids. A CT or MRI scan of the head is necessary in patients with a history of brain metastases to document the stability of prior lesions~* Grade \> 2 peripheral neuropathy~* Known bleeding diathesis or concurrent treatment with anticoagulants except patients on non-therapeutic line maintenance coumadin~* Pregnant or nursing women. NOTE: Women of child-bearing potential must agree to use adequate contraception (sterile or surgically sterile; hormonal or barrier method of birth control; or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately~* Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy~* Known infection with HIV, hepatitis B, or hepatitis C~* Serious nonmalignant disease that could compromise protocol objectives in the opinion of the investigator and/or the sponsor~* Patients who are currently receiving any other investigational agent. Subjects who have used a previous antisense oligonucleotide in the last 90 days will be excluded~* Unwillingness or inability to comply with procedures required in this protocol~* Any deviation from these inclusion/exclusion criteria must be discussed with the sponsor prior to enrolling patient.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval